Base de dados : MEDLINE
Pesquisa : D27.505.954.122.250 [Categoria DeCS]
Referências encontradas : 2785 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 279 ir para página                         

  1 / 2785 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29292916
[Au] Autor:Jonsson P; Lindelöf B; Nordlind K; Bornstein S
[Ad] Endereço:Karolinska Universitetssjukhuset - Hudkliniken Stockholm, Sweden Karolinska Universitetssjukhuset - Hudkliniken Stockholm, Sweden.
[Ti] Título:Vid klåda, tänk alltid på skabb!.
[So] Source:Lakartidningen;114, 2017 Nov 07.
[Is] ISSN:1652-7518
[Cp] País de publicação:Sweden
[La] Idioma:swe
[Ab] Resumo:In case of pruritus, always consider scabies! Scabies is an itching skin disease caused by the mite Sarcoptes scabiei which affects more than 100 million people worldwide. Regarded as a neglected tropical disease by the WHO, it is a major public health burden in endemic areas. As direct skin-to-skin contact is the main route of transmission family members and sexual partners are often affected. Typical presentation includes a severely pruritic rash with predilection for the extremities and the trunk. Definitive diagnosis relies on microscopic identification of the mites. Future, more efficient, diagnostic methods may include serological testing or PCR for S. scabiei DNA. A benzyl benzoate and disulfiram based lotion, Tenutex, is the treatment of choice in Sweden with topical permethrin or oral ivermectin being used in certain cases. Scabies is an important diagnosis to consider in all patients presenting with pruritus.
[Mh] Termos MeSH primário: Escabiose
[Mh] Termos MeSH secundário: Idoso
Animais
Antiparasitários/administração & dosagem
Antiparasitários/uso terapêutico
Criança
Seres Humanos
Lactente
Prurido/parasitologia
Sarcoptes scabiei
Escabiose/diagnóstico
Escabiose/tratamento farmacológico
Escabiose/epidemiologia
Escabiose/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiparasitic Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE


  2 / 2785 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29288945
[Au] Autor:Zhang HZ; Zhao ZL; Zhou CH
[Ad] Endereço:School of Pharmacy, Linyi University, Linyi 276000, China. Electronic address: zhanghuizhen@lyu.edu.cn.
[Ti] Título:Recent advance in oxazole-based medicinal chemistry.
[So] Source:Eur J Med Chem;144:444-492, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Oxazole compounds containing nitrogen and oxygen atoms in the five-membered aromatic ring are readily able to bind with a variety of enzymes and receptors in biological systems via diverse non-covalent interactions, and thus display versatile biological activities. The related researches in oxazole-based derivatives including oxazoles, isoxazoles, oxazolines, oxadiazoles, oxazolidones, benzoxazoles and so on, as medicinal drugs have been an extremely active topic, and numerous excellent achievements have been acquired. Noticeably, a large number of oxazole compounds as clinical drugs or candidates have been frequently employed for the treatment of various types of diseases, which have shown their large development value and wide potential as medicinal agents. This work systematically reviewed the recent researches and developments of the whole range of oxazole compounds as medicinal drugs, including antibacterial, antifungal, antiviral, antitubercular, anticancer, anti-inflammatory and analgesic, antidiabetic, antiparasitic, anti-obesitic, anti-neuropathic, antioxidative as well as other biological activities. The perspectives of the foreseeable future in the research and development of oxazole-based compounds as medicinal drugs are also presented. It is hoped that this review will serve as a stimulant for new thoughts in the quest for rational designs of more active and less toxic oxazole medicinal drugs.
[Mh] Termos MeSH primário: Oxazóis/farmacologia
[Mh] Termos MeSH secundário: Analgésicos/química
Analgésicos/farmacologia
Antibacterianos/química
Antibacterianos/farmacologia
Anti-Inflamatórios não Esteroides/química
Anti-Inflamatórios não Esteroides/farmacologia
Fármacos Antiobesidade/química
Fármacos Antiobesidade/farmacologia
Antifúngicos/química
Antifúngicos/farmacologia
Antineoplásicos/química
Antineoplásicos/farmacologia
Antioxidantes/química
Antioxidantes/farmacologia
Antiparasitários/química
Antiparasitários/farmacologia
Antituberculosos/química
Antituberculosos/farmacologia
Antivirais/química
Antivirais/farmacologia
Química Farmacêutica
Seres Humanos
Hipoglicemiantes/química
Hipoglicemiantes/farmacologia
Estrutura Molecular
Oxazóis/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics); 0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Anti-Obesity Agents); 0 (Antifungal Agents); 0 (Antineoplastic Agents); 0 (Antioxidants); 0 (Antiparasitic Agents); 0 (Antitubercular Agents); 0 (Antiviral Agents); 0 (Hypoglycemic Agents); 0 (Oxazoles)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171231
[St] Status:MEDLINE


  3 / 2785 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29220340
[Au] Autor:Savchenko LP; Mishchenko VA; Georgiyants VA
[Ad] Endereço:Department of Quality, Standardization and Certification of Drugs, Institute of Pharmacy Professionals Qualification Improvement, National University of Pharmacy, Kharkiv, Ukraine. savchenkolesia@gmail.com.
[Ti] Título:Validation of the Technological Process of the Preparation "Milk by Vidal".
[So] Source:Int J Pharm Compd;21(6):513-517, 2017 Nov-Dec.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Validation was performed on the technological process of the compounded preparation "Milk by Vidal" in accordance with the requirements of the regulatory framework of Ukraine. Critical stages of formulation which can affect the quality of the finished preparation were considered during the research. The obtained results indicated that the quality of the finished preparation met the requirements of the State Pharmacopoeia of Ukraine.
[Mh] Termos MeSH primário: Composição de Medicamentos/normas
Tecnologia Farmacêutica/normas
[Mh] Termos MeSH secundário: Anti-Infecciosos Locais/química
Antiparasitários/química
Química Farmacêutica
Controle de Qualidade
Ucrânia
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Anti-Infective Agents, Local); 0 (Antiparasitic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  4 / 2785 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449318
[Au] Autor:Zammarchi L; Bonati M; Strohmeyer M; Albonico M; Requena-Méndez A; Bisoffi Z; Nicoletti A; García HH; Bartoloni A; COHEMI Project Study Group
[Ad] Endereço:Unità di Malattie Infettive, Università Degli Studi di Firenze, Florence, Italy.
[Ti] Título:Screening, diagnosis and management of human cysticercosis and Taenia solium taeniasis: technical recommendations by the COHEMI project study group.
[So] Source:Trop Med Int Health;22(7):881-894, 2017 07.
[Is] ISSN:1365-3156
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Neurocysticercosis, the central nervous system's localised form of cysticercosis, is considered to be the leading cause of epilepsy in the developing world. In Europe, the disease is mainly imported and affects both immigrants and travellers. However, autochthonous cases of cysticercosis in low-endemic countries could also originate from Taenia solium carriers (migrants or travellers) who acquired taeniasis overseas. Management of cysticercosis is a challenge for European healthcare providers as they are often hardly aware of this infection and have little familiarity in managing this disease. This study provides a summary of recommendations concerning screening, diagnosis and management of cysticercosis and T. solium taeniasis in Europe drawn up by nine experts in migrant health and imported diseases with experience in cysticercosis and T. solium taeniasis.
[Mh] Termos MeSH primário: Antiparasitários/uso terapêutico
Cisticercose/diagnóstico
Cisticercose/tratamento farmacológico
Taenia solium/isolamento & purificação
[Mh] Termos MeSH secundário: Animais
Europa (Continente)
Seres Humanos
América Latina
Migrantes
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antiparasitic Agents)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1111/tmi.12887


  5 / 2785 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29253862
[Au] Autor:Luroni LT; Gabriel M; Tukahebwa E; Onapa AW; Tinkitina B; Tukesiga E; Nyaraga M; Auma AM; Habomugisha P; Byamukama E; Oguttu D; Katabarwa M; Unnasch TR
[Ad] Endereço:Vector Control Division, Ministry of Health, Kampala, Uganda.
[Ti] Título:The interruption of Onchocerca volvulus and Wuchereria bancrofti transmission by integrated chemotherapy in the Obongi focus, North Western Uganda.
[So] Source:PLoS One;12(12):e0189306, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTERVENTION: Few studies have documented the interruption of onchocerciasis and Lymphatic Filariasis (LF) by integrated chemotherapy in Uganda. The study describes the interruption of transmission of the two diseases co-endemic in Obongi focus, north western Uganda. Base line data for Onchocerciasis and LF were collected in 1994 and 2006, respectively. Annual mass drug administration for onchocerciasis (Ivermectin) and Lymphatic Filariasis (Ivermectin + albendazole) was conducted for 20 and 6 years, respectively. Thereafter, assessments by skin snip, larval searches in rivers and human landing catches were performed. Children <10 years were screened for IgG4 antibodies using Ov16 ELISA technique in 2013. LF Pre-TAS and TAS1 were conducted in sentinel sites. ITN coverage and utilization for the implementation unit was also reported. INTERVENTION COVERAGE: Onchocerciasis treatment coverage was <80% but improved with the introduction of CDTI in 1999. While for LF, effective coverage of >65% was achieved in the six treatment rounds. Household ownership of ITN's and utilization was 96% and 72.4%., respectively. IMPACT: Parasitological examinations conducted for onchocerciasis among 807 adults and children, revealed a reduction in mf prevalence from 58% in 1994 to 0% in 2012. Entomological monitoring conducted at the two sites had no single Simulium damnosum fly caught. Serological analysis using Ov16 ELISA for onchocerciasis revealed that out of the 3,308 children <10 years old screened in 2013, only 3/3308 (0.091%) positive cases were detected. All Ov16 positive children were negative when tested for patent infection by skin snip PCR. A reduction in LF microfilaria prevalence from 2.5% (n = 13/522) in 2006 to 0.0% (n = 602) in 2014 was observed. LF TAS1 conducted in 2015 among 1,532 children 6-7 years, all were negative for antigens of W. bancrofti. CONCLUSION: The results concluded that interruption of onchocerciasis and LF has been achieved.
[Mh] Termos MeSH primário: Antiparasitários/uso terapêutico
Filariose Linfática/tratamento farmacológico
Onchocerca volvulus
Oncocercose/tratamento farmacológico
Wuchereria bancrofti
[Mh] Termos MeSH secundário: Adolescente
Albendazol/administração & dosagem
Animais
Criança
Pré-Escolar
Filariose Linfática/epidemiologia
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Imunoglobulina G/sangue
Ivermectina/administração & dosagem
Masculino
Oncocercose/epidemiologia
Prevalência
Uganda
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiparasitic Agents); 0 (Immunoglobulin G); 70288-86-7 (Ivermectin); F4216019LN (Albendazole)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189306


  6 / 2785 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29175675
[Au] Autor:Bala V; Chhonker YS
[Ad] Endereço:Department of Pharmaceutical Sciences, Mohanlal Sukhadia University, Udaipur, 313001, India. Electronic address: veenu2bala@mlsu.ac.in.
[Ti] Título:Recent developments in anti-Trichomonas research: An update review.
[So] Source:Eur J Med Chem;143:232-243, 2018 Jan 01.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Trichomonas vaginalis is a major non-viral sexually-transmitted infection resulted into serious obstetrical and gynecological troubles. The increasing resistance to nitroimidazole therapy and recurrence makes it crucial to develop new drugs against trichomoniasis. Over the past few years, a large number of research articles highlighting the synthetic and natural product research to combat Trichomonas vaginalis have been published. Electronic databases were searched to collect all data from the year 2006 through June 2017 for anti-Trichomonas activity potential of synthetic and natural products. This review article put together the synthetic and natural product research to find out an effective metronidazole alternative to cure trichomoniasis.
[Mh] Termos MeSH primário: Antiparasitários/farmacologia
Produtos Biológicos/farmacologia
Tricomoníase/tratamento farmacológico
Trichomonas/efeitos dos fármacos
[Mh] Termos MeSH secundário: Antiparasitários/química
Antiparasitários/isolamento & purificação
Produtos Biológicos/química
Produtos Biológicos/isolamento & purificação
Relação Dose-Resposta a Droga
Seres Humanos
Estrutura Molecular
Testes de Sensibilidade Parasitária
Relação Estrutura-Atividade
Tricomoníase/parasitologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiparasitic Agents); 0 (Biological Products)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  7 / 2785 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29223887
[Au] Autor:Panozzo-Zénere EA; Porta EOJ; Arrizabalaga G; Fargnoli L; Khan SI; Tekwani BL; Labadie GR
[Ad] Endereço:Instituto de Química Rosario (IQUIR-CONICET), Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, S2002LRK, Rosario, Argentina.
[Ti] Título:A minimalistic approach to develop new anti-apicomplexa polyamines analogs.
[So] Source:Eur J Med Chem;143:866-880, 2018 Jan 01.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:The development of new chemical entities against the major diseases caused by parasites is highly desired. A library of thirty diamines analogs following a minimalist approach and supported by chemoinformatics tools have been prepared and evaluated against apicomplexan parasites. Different member of the series of N,N'-disubstituted aliphatic diamines shown in vitro activities at submicromolar concentrations and high levels of selectivity against Toxoplasma gondii and in chloroquine-sensitive and resistant-strains of Plasmodium falciparum. In order to demonstrate the importance of the secondary amines, ten N,N,N',N'-tetrasubstituted aliphatic diamines derivatives were synthesized being considerably less active than their disubstituted counterpart. Theoretical studies were performed to establish the electronic factors that govern the activity of the compounds.
[Mh] Termos MeSH primário: Antiparasitários/farmacologia
Apicomplexa/efeitos dos fármacos
Poliaminas/farmacologia
[Mh] Termos MeSH secundário: Antiparasitários/síntese química
Antiparasitários/química
Relação Dose-Resposta a Droga
Estrutura Molecular
Testes de Sensibilidade Parasitária
Plasmodium falciparum/efeitos dos fármacos
Poliaminas/síntese química
Poliaminas/química
Relação Estrutura-Atividade
Toxoplasma/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiparasitic Agents); 0 (Polyamines)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180101
[Lr] Data última revisão:
180101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171211
[St] Status:MEDLINE


  8 / 2785 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29190292
[Au] Autor:Mahanty S; Orrego MA; Cangalaya C; Adrianzen MP; Arroyo G; Calcina J; Gonzalez AE; García HH; Guerra-Giraldez C; Nash TE; Cysticercosis Working Group in Peru
[Ad] Endereço:Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
[Ti] Título:TNF-α blockade suppresses pericystic inflammation following anthelmintic treatment in porcine neurocysticercosis.
[So] Source:PLoS Negl Trop Dis;11(11):e0006059, 2017 Nov.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Neurocysticercosis (NCC) is an infection of the brain with the larval cyst of the tapeworm, Taenia solium. Cysticidal treatment induces parasite killing resulting in a post inflammatory response and seizures, which generally requires corticosteroid treatment to control inflammation. The nature of this response and how to best control it is unclear. We investigated the anti-inflammatory effects of pretreatment with etanercept (ETN), an anti-tumor necrosis factor agent, or dexamethasone (DEX), a high potency corticosteroid, on the post treatment inflammatory response in naturally infected pigs with neurocysticercosis after a single dose of the cysticidal drug praziquantel (PZQ). METHODOLOGY/PRINCIPAL FINDINGS: We followed the methods from a previously developed treatment model of NCC in naturally infected swine. The four study groups of infected pigs included 3 groups treated with PZQ on day 0: PZQ-treated alone (100 mg/kg PO; n = 9), pretreated with dexamethasone (DEX, 0.2 mg/kg IM administered on days -1, +1 and +3; n = 6), and pretreated with etanercept (ETN, 25 mg IM per animal on days -7 and 0; n = 6). The fourth group remained untreated (n = 3). As measured by quantitative RT-PCR, ETN pretreatment depressed transcription of a wide range of proinflammatory, regulatory and matrix protease encoding genes at 120 hr post PZQ treatment in capsules of cysts that demonstrated extravasated Evans Blue (EB) (a measure of blood brain barrier dysfunction) compared to animals not receiving ETN. Transcription was significantly depressed for the proinflammatory genes tumor necrosis factor (TNF)-α, and interferon (IFN)-γ; the inflammation regulating genes cytotoxic T-lymphocyte-associated protein (CTLA)4, interleukin (IL)-13 and transforming growth factor (TGF)-ß; the tissue remodeling genes matrix metalloprotease (MMP)1 and 9, tissue inhibitors of metalloproteases (TIMP)1 and 2, and the genes regulating endothelial function vascular endothelial growth factor (VEGF)1, angiopoietin (Ang)1, Ang 2, and platelet endothelial cell adhesion molecule (PECAM)-1. In contrast, transcription was only modestly decreased in the DEX pretreated pigs compared to PZQ alone, and only for TNF-α, IL-6, IFN-γ, TGF-ß and Ang1. IL-10 was not affected by either ETN or DEX pretreatments. The degree of inflammation, assessed by semi-quantitative inflammatory scores, was modestly decreased in both ETN and DEX pretreated animals compared to PZQ treated pigs whereas cyst damage scores were moderately decreased only in cysts from DEX pretreated pigs. However, the proportion of cysts with EB extravasation was not significantly changed in ETN and DEX pretreated groups. CONCLUSIONS/SIGNIFICANCE: Overall, TNF-α blockade using ETN treatment modulated expression of a large variety of genes that play a role in induction and control of inflammation and structural changes. In contrast the number of inflammatory cells was only moderately decreased suggesting weaker effects on cell migration into the inflammatory capsules surrounding cysts than on release of modulatory molecules. Taken together, these data suggest that TNF-α blockade may provide a viable strategy to manage post-treatment pericystic inflammation that follows antiparasitic therapy for neurocysticercosis.
[Mh] Termos MeSH primário: Etanercepte/administração & dosagem
Imunossupressores/administração & dosagem
Inflamação/prevenção & controle
Neurocisticercose/veterinária
Doenças dos Suínos/tratamento farmacológico
Fator de Necrose Tumoral alfa/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Anticestoides/uso terapêutico
Antiparasitários/efeitos adversos
Antiparasitários/uso terapêutico
Barreira Hematoencefálica/efeitos dos fármacos
Encéfalo/parasitologia
Citocinas/genética
Citocinas/imunologia
Dexametasona/administração & dosagem
Dexametasona/efeitos adversos
Etanercepte/efeitos adversos
Imunossupressores/efeitos adversos
Interferon gama/genética
Interferon gama/imunologia
Neurocisticercose/complicações
Neurocisticercose/tratamento farmacológico
Neurocisticercose/imunologia
Praziquantel/administração & dosagem
Praziquantel/efeitos adversos
Praziquantel/uso terapêutico
Suínos
Doenças dos Suínos/imunologia
Taenia solium/efeitos dos fármacos
Fator de Necrose Tumoral alfa/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticestodal Agents); 0 (Antiparasitic Agents); 0 (Cytokines); 0 (Immunosuppressive Agents); 0 (Tumor Necrosis Factor-alpha); 6490C9U457 (Praziquantel); 7S5I7G3JQL (Dexamethasone); 82115-62-6 (Interferon-gamma); OP401G7OJC (Etanercept)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0006059


  9 / 2785 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29187956
[Au] Autor:Elmehdi E; Zerkly B
[Ad] Endereço:Service de Traumatologie Orthopedie du Groupe Hospitalier Publique du Sud de l'Oise(GHPSO), bp60100 Creil, France.
[Ti] Título:[Leg ulcer revealing cutaneous leishmaniasis].
[Ti] Título:Ulcère de jambe révélant la leishmaniose cutanée..
[So] Source:Pan Afr Med J;27:287, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:fre
[Ab] Resumo:Leishmaniases are parasitic diseases occurring in endemic tropical and subtropical areas and caused by protozoa of the genus leishmania, transmitted by a diptera (sand fly). We here report a case of topical cutaneous leishmaniasis discovered in a 15-year old boy with painless ulcer on his left leg, who had been staying in South Africa. Clinical examination showed painless non-itchy ulcer, occurred 1 month before, on the antero-internal part of his left leg with crusts and scars caused by insect bites, all evolving in a context of patient's general health status, without mucosal or visceral lesions. Skin biopsy allowed specific parasitologic diagnosis revealing topical zoonotic cutaneous leishmaniasis caused by L. major. The patient underwent topical treatment based on paramomycin and oral fluconazole resulting in ulcer healing at the end of 2 months.
[Mh] Termos MeSH primário: Úlcera da Perna/diagnóstico
Leishmaniose Cutânea/diagnóstico
Zoonoses/diagnóstico
[Mh] Termos MeSH secundário: Administração Tópica
Adolescente
Animais
Antiparasitários/administração & dosagem
Biópsia
Fluconazol/administração & dosagem
Seres Humanos
Úlcera da Perna/tratamento farmacológico
Úlcera da Perna/parasitologia
Leishmania major/isolamento & purificação
Leishmaniose Cutânea/tratamento farmacológico
Leishmaniose Cutânea/patologia
Masculino
Paromomicina/administração & dosagem
Resultado do Tratamento
Zoonoses/tratamento farmacológico
Zoonoses/parasitologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiparasitic Agents); 61JJC8N5ZK (Paromomycin); 8VZV102JFY (Fluconazole)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.27.287.13090


  10 / 2785 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28466558
[Au] Autor:Matricoti I; Maina E
[Ad] Endereço:Servizi Dermatologici Veterinari, Bologna, 40125, Italy.
[Ti] Título:The use of oral fluralaner for the treatment of feline generalised demodicosis: a case report.
[So] Source:J Small Anim Pract;58(8):476-479, 2017 Aug.
[Is] ISSN:1748-5827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:There is little agreement on the most effective and safest treatment for feline demodicosis. Protocols generally consist of long-lasting therapy courses based on rinses, subcutaneous injections, oral drug administration or repeated spot-on formulation and the efficacy of most of these is poorly documented. Many of these products have also been associated with adverse effects and may be difficult to administer in cats, leading to poor owner compliance and treatment failure. This case report describes the successful use of fluralaner in treating a generalised form of demodicosis caused by Demodex cati in an adult cat that was probably triggered by chronic glucocorticoid administration. After a single oral dose of 28 mg/kg fluralaner, negative skin scrapings were obtained within one month and clinical cure within two months. No side effects were observed. Larger studies are needed to evaluate the efficacy of fluralaner in treating feline generalised demodicosis.
[Mh] Termos MeSH primário: Antiparasitários/uso terapêutico
Doenças do Gato/tratamento farmacológico
Isoxazóis/uso terapêutico
Infestações por Ácaros/veterinária
[Mh] Termos MeSH secundário: Administração Oral
Animais
Gatos
Feminino
Infestações por Ácaros/tratamento farmacológico
Ácaros/efeitos dos fármacos
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (A1443 compound); 0 (Antiparasitic Agents); 0 (Isoxazoles)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1111/jsap.12682



página 1 de 279 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde